Atara Biotherapeutics Faces Class Action for Misleading Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ATRA?
Source: Globenewswire
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, indicating significant legal risks that could impact stock price and market confidence.
- FDA Regulatory Risks: The lawsuit alleges that Atara misled investors regarding the regulatory prospects of its lead drug candidate, tabelecleucel, due to manufacturing issues and deficiencies in the ALLELE study, which could prevent FDA approval of its Biologics License Application (BLA), significantly affecting the company's financial condition.
- Stock Price Plunge: On January 12, 2026, Atara announced that the FDA issued another Complete Response Letter (CRL) regarding the tabelecleucel BLA, causing the stock price to plummet by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by May 22, 2026, to serve as lead plaintiffs in the class action, and even those who choose not to participate can still be eligible for recovery, providing investors with a potential avenue for legal recourse.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.990
Low
18.00
Averages
21.50
High
25.00
Current: 4.990
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating significant legal risks for the company.
- Regulatory Scrutiny: On January 16, 2025, Atara received a Complete Response Letter from the FDA regarding its tabelecleucel BLA, resulting in a 40.5% drop in stock price, highlighting serious compliance issues that could hinder future financing and erode market confidence.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's Investigational New Drug applications due to GMP compliance issues identified during inspections, exacerbating investor concerns about the company's future and causing a further 7.91% decline in stock price.
- Severe Market Reaction: Following another Complete Response Letter from the FDA on January 12, 2026, Atara's stock plummeted by 56.99%, reflecting a drastic loss of investor confidence in the company's product development prospects, which may lead to capital withdrawal and impact long-term strategic plans.
See More
Atara Biotherapeutics Faces Class Action for Misleading Investors
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, indicating significant legal risks that could impact stock price and market confidence.
- FDA Regulatory Risks: The lawsuit alleges that Atara misled investors regarding the regulatory prospects of its lead drug candidate, tabelecleucel, due to manufacturing issues and deficiencies in the ALLELE study, which could prevent FDA approval of its Biologics License Application (BLA), significantly affecting the company's financial condition.
- Stock Price Plunge: On January 12, 2026, Atara announced that the FDA issued another Complete Response Letter (CRL) regarding the tabelecleucel BLA, causing the stock price to plummet by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by May 22, 2026, to serve as lead plaintiffs in the class action, and even those who choose not to participate can still be eligible for recovery, providing investors with a potential avenue for legal recourse.
See More
Reminder for Atara Biotherapeutics Investors on Class Action Deadline
- FDA Regulatory Crisis: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its Biologics License Application for EBVALLO was not approved, causing a 40.5% drop in stock price to $7.83 per share, severely impacting investors.
- Clinical Trial Hold: On January 21, 2025, Atara disclosed that the FDA placed a clinical hold on its active IND applications due to GMP compliance issues found during inspections, leading to a further 7.9% decline in stock price to $6.05 per share, exacerbating investor losses.
- Another CRL Issued: On January 12, 2026, Atara disclosed another Complete Response Letter from the FDA stating that the EBVALLO application could not be approved due to trial design issues, resulting in a 56.99% drop in stock price to $5.88 per share, increasing risks for investors.
- Class Action Initiated: A class action lawsuit has been initiated against Atara for failing to disclose manufacturing issues and clinical trial deficiencies throughout the class period, misleading investors about the company's prospects, with a deadline for lead plaintiff motions set for May 22, 2026.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the truth emerged, likely having a significant negative impact on the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first in 2017 for the number of settlements, demonstrating its expertise in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting a law firm with a successful track record to ensure optimal representation and support in the class action.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the regulatory prospects of the tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure optimal representation in litigation and avoid firms that merely act as intermediaries.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, including manufacturing issues and deficiencies in the ALLELE study, which may hinder FDA approval of the tabelecleucel Biologics License Application.
- Increased Regulatory Risks: The aforementioned manufacturing issues expose Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant negative impact on the company's financial condition, exacerbating the risk of investor losses.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to help investors understand their rights and potential legal options.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating significant legal risks for the company.
- Regulatory Scrutiny: On January 16, 2025, Atara received a Complete Response Letter from the FDA regarding its tabelecleucel BLA, resulting in a 40.5% drop in stock price, highlighting serious compliance issues that could hinder future financing and erode market confidence.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's Investigational New Drug applications due to GMP compliance issues identified during inspections, exacerbating investor concerns about the company's future and causing a further 7.91% decline in stock price.
- Severe Market Reaction: Following another Complete Response Letter from the FDA on January 12, 2026, Atara's stock plummeted by 56.99%, reflecting a drastic loss of investor confidence in the company's product development prospects, which may lead to capital withdrawal and impact long-term strategic plans.
See More
Atara Biotherapeutics Faces Class Action for Misleading Investors
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, indicating significant legal risks that could impact stock price and market confidence.
- FDA Regulatory Risks: The lawsuit alleges that Atara misled investors regarding the regulatory prospects of its lead drug candidate, tabelecleucel, due to manufacturing issues and deficiencies in the ALLELE study, which could prevent FDA approval of its Biologics License Application (BLA), significantly affecting the company's financial condition.
- Stock Price Plunge: On January 12, 2026, Atara announced that the FDA issued another Complete Response Letter (CRL) regarding the tabelecleucel BLA, causing the stock price to plummet by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by May 22, 2026, to serve as lead plaintiffs in the class action, and even those who choose not to participate can still be eligible for recovery, providing investors with a potential avenue for legal recourse.
See More
Reminder for Atara Biotherapeutics Investors on Class Action Deadline
- FDA Regulatory Crisis: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its Biologics License Application for EBVALLO was not approved, causing a 40.5% drop in stock price to $7.83 per share, severely impacting investors.
- Clinical Trial Hold: On January 21, 2025, Atara disclosed that the FDA placed a clinical hold on its active IND applications due to GMP compliance issues found during inspections, leading to a further 7.9% decline in stock price to $6.05 per share, exacerbating investor losses.
- Another CRL Issued: On January 12, 2026, Atara disclosed another Complete Response Letter from the FDA stating that the EBVALLO application could not be approved due to trial design issues, resulting in a 56.99% drop in stock price to $5.88 per share, increasing risks for investors.
- Class Action Initiated: A class action lawsuit has been initiated against Atara for failing to disclose manufacturing issues and clinical trial deficiencies throughout the class period, misleading investors about the company's prospects, with a deadline for lead plaintiff motions set for May 22, 2026.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the truth emerged, likely having a significant negative impact on the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first in 2017 for the number of settlements, demonstrating its expertise in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting a law firm with a successful track record to ensure optimal representation and support in the class action.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the regulatory prospects of the tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure optimal representation in litigation and avoid firms that merely act as intermediaries.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, including manufacturing issues and deficiencies in the ALLELE study, which may hinder FDA approval of the tabelecleucel Biologics License Application.
- Increased Regulatory Risks: The aforementioned manufacturing issues expose Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant negative impact on the company's financial condition, exacerbating the risk of investor losses.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to help investors understand their rights and potential legal options.
See More
